Development of a RNA-Seq based prognostic signature for colon cancer Online publication date: Wed, 31-Mar-2021
by Bjarne Bartlett; Yong Zhu; Mark Menor; Vedbar S. Khadka; Jicai Zhang; Jie Zheng; Bin Jiang; Youping Deng
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 13, No. 5/6, 2020
Abstract: RNA-Seq data has recently been used to successfully develop prognostic signatures to predict cancer patients who will have a worse prognosis. We designed a study to ascertain whether a prognostic model, based on RNA-Seq data, would have clinical utility for predicting survival in patients with colon adenocarcinomas (COAD). Of particular interest are early stage COAD patients, for whom the benefits of adjuvant therapy are unclear. High-risk patients predicted by our 5-gene, RNA-Seq signature had significantly shorter survival in both the training (p = 0.00) and test (p = 0.003) cohorts. Here we present an RNA-Seq prognostic signature that can identify high-risk COAD patients with shorter survival. This signature would have clinical utility as part of an RNA-Seq screening program, particularly for identifying early stage COAD patients who could be recommended adjuvant therapy after resection based on the results of this prognostic signature.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com